Zymeworks Dirección
Dirección controles de criterios 2/4
El CEO de Zymeworks es Ken Galbraith , nombrado en Jan 2022, tiene una permanencia de 2.83 años. compensación anual total es $3.37M, compuesta por 18.5% salario y 81.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.035% de las acciones de la empresa, por valor de $337.43K. La antigüedad media del equipo directivo y de la junta directiva es de 1.8 años y 1.6 años, respectivamente.
Información clave
Ken Galbraith
Chief Executive Officer (CEO)
US$3.4m
Compensación total
| Porcentaje del salario del CEO | 18.5% |
| Permanencia del CEO | 2.8yrs |
| Participación del CEO | 0.03% |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 1.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 34% But Growth Is Lacking
Nov 08
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
Nov 04Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 03Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook
Nov 01Zymeworks Approaching A Moment Of Truth With Zanidatamab
Sep 27Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week
Aug 07Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up
Jul 26Zymeworks: A Somewhat Complicated Story
Jul 09Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
Jun 12Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business
May 03Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$114m |
| Jun 30 2024 | n/a | n/a | -US$113m |
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$3m | US$625k | -US$119m |
| Sep 30 2023 | n/a | n/a | US$205m |
| Jun 30 2023 | n/a | n/a | US$186m |
| Mar 31 2023 | n/a | n/a | US$173m |
| Dec 31 2022 | US$7m | US$582k | US$124m |
| Sep 30 2022 | n/a | n/a | -US$224m |
| Jun 30 2022 | n/a | n/a | -US$237m |
| Mar 31 2022 | n/a | n/a | -US$240m |
| Dec 31 2021 | n/a | n/a | -US$212m |
| Sep 30 2021 | n/a | n/a | -US$211m |
| Jun 30 2021 | n/a | n/a | -US$223m |
| Mar 31 2021 | n/a | n/a | -US$194m |
| Dec 31 2020 | n/a | n/a | -US$181m |
| Sep 30 2020 | n/a | n/a | -US$215m |
| Jun 30 2020 | n/a | n/a | -US$173m |
| Mar 31 2020 | n/a | n/a | -US$163m |
| Dec 31 2019 | US$167k | n/a | -US$145m |
Compensación vs. Mercado: La compensación total ($USD3.37M) de Ken está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.18M).
Compensación vs. Ingresos: La compensación de Ken ha sido consistente con los resultados de la empresa en el último año.
CEO
Ken Galbraith (61 yo)
2.8yrs
Permanencia
US$3,374,876
Compensación
Mr. Kenneth H. Galbraith, also known as Ken, C. A., is Director of AudienceView Ticketing Corporation. He serves as Chairman of Zomp. He is Director of NeurAxon Inc. He is CEO & Chairman of the Board of Zy...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board | 2.8yrs | US$3.37m | 0.035% $ 337.4k | |
| Chief Scientific Officer | 2.3yrs | US$1.68m | 0.011% $ 104.7k | |
| Executive VP and Chief Business & Financial Officer | less than a year | sin datos | sin datos | |
| Executive VP and Head of Technical & Manufacturing Operations | no data | sin datos | sin datos | |
| Director of Investor Relations | no data | sin datos | sin datos | |
| Senior VP | no data | sin datos | sin datos | |
| Senior Manager of Corporate Communications | no data | sin datos | sin datos | |
| Vice President of Corporate Development | no data | sin datos | sin datos | |
| Vice President of Human Resources & DEI | 1.8yrs | sin datos | sin datos | |
| Executive VP & Chief Medical Officer | no data | sin datos | sin datos | |
| Senior Vice President of Process Sciences | less than a year | sin datos | sin datos | |
| Senior Director of Corporate Affairs | no data | sin datos | sin datos |
1.8yrs
Permanencia media
61yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ZYME no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman of the Board | 2.8yrs | US$3.37m | 0.035% $ 337.4k | |
| Independent Director | 7.8yrs | US$264.00k | 0% $ 0 | |
| Independent Director | less than a year | US$441.02k | 0% $ 0 | |
| Independent Director | less than a year | sin datos | 0% $ 0 | |
| Independent Director | 4.7yrs | US$262.46k | 0% $ 0 | |
| Lead Independent Director | 5.4yrs | US$261.83k | 0% $ 0 | |
| Independent Director | less than a year | sin datos | 0% $ 0 | |
| Independent Director | 1.6yrs | US$555.15k | 0% $ 0 | |
| Independent Director | 5.4yrs | US$263.83k | 0.011% $ 106.5k | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | 1.4yrs | US$508.97k | 0% $ 0 | |
| no data | sin datos | sin datos |
1.6yrs
Permanencia media
60yo
Promedio de edad
Junta con experiencia: La junta directiva de ZYME no se considera experimentada (1.6 años de permanencia promedio), lo que sugiere una nueva junta directiva.